The natriuretic peptide family: turning hormones into drugs

in Journal of Endocrinology
Authors:
M. R. Wilkins
Search for other papers by M. R. Wilkins in
Current site
Google Scholar
PubMed
Close
,
D. J. Nunez
Search for other papers by D. J. Nunez in
Current site
Google Scholar
PubMed
Close
, and
J. Wharton
Search for other papers by J. Wharton in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

Introduction

The past 10 years have witnessed the discovery of a new peptide family, the natriuretic peptides, which may rival the renin-angiotensin system in their contribution to cardiovascular homoeostasis. The first member to be identified and the most intensively studied is atrial natriuretic peptide (ANP) (DeBold et al. 1981: Flynn et al. 1983; Oikawa et al. 1984). More recently, brain natriuretic peptide (BNP) (Sudoh et al. 1988), C-type natriuretic peptide (CNP) (Sudoh et al. 1990) and urodilatin (Feller et al. 1989) have been isolated and their amino acid sequences determined (Fig. 1). The structural hallmark of this family is a 17-amino acid ring formed by a disulphide bond. From the functional viewpoint, their biological effects are mediated principally by receptors with integral guanylyl cyclase activity. The term 'natriuretic peptide family' is one of convenience ; recent studies suggest that CNP has little natriuretic activity and in some situations may even be

 

  • Collapse
  • Expand